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Background: Since Hepatitis-B patients coinfected/
superinfected with Hepatitis-D virus are increasing in South-
East Asian countries like Pakistan and India, so the study
was designed to observe the effects of antiviral drugs like
lamivudine on sero-conversion of HBeAg positive cases.
Methods: This study was conducted at Hepatology clinic,
Lahore Pakistan, over a period of 2 years from 2007 to
2009. A total of 97 ELISA conﬁrmed Hepatitis-B positive
patients with deranged liver functions for 6 months were
recruited. All were screened for HBeAg, HBV-DNA and anti-
HDV using ELISA test. They were subdivided in 2 groups.
GroupA included patients who were HBeAg and HBV-DNA
positive but Anti-HDV negative, while group B comprised
of patients positive for HBeAg, HBV-DNA and Anti-HDV (all
positive). Reverse transcriptase inhibitor (RTI), lamivudine
in a dose of 100mg/day was given to all till sero-conversion.
Results: Out of total 97 patients 64% (n = 62) were males,
mean age 56±4 years. 55 cases were in group A and 42
were in group B. At the beginning of study, mean HBeAg was
284±179 in group A and 137±151 in group B. Within a period
of 6 months, ALT became normal in 70% patients (n = 38)
among group A, and 19% (n = 8) among group B. Serum viral
markers did not change much till 1 year of treatment and
was signiﬁcantly slower among group B. 34% (n = 19) patients
in group A and 12% (n = 5) patients in group B sero-converted
completely at the end of 2 years therapy.
Conclusions: Hepatitis-B patients co-infected with
Hepatitis-D virus have a chance of seroconversion and still
the effective therapy options are available to treat such
scenario.
Effort should be maximized to catch the diagnosis earlier
and start the therapy in an optimal mode so as to get
enhanced beneﬁts of antiviral drugs like lamivudine.
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Background: Public demand for higher standards of
screening for infections agents in transfusion products has
fueled the development and advancement of nucleic acid
test technology. This report describes a comparation of the
HBV NAT screening results by 1 foreign and 4 domestic
HBV/HCV/HIV-1 NAT screening kits.
Method: 1 foreign and 4 domestic HBV/HCV/HIV-1 NAT
screening kits were applied to detect 393 plasma samples
from chronic hepatitis B patients and healthy people and
an additional plasma for sensitivity, These results were
compared with the result of Roche COBAS TaqMan HBV Test
for quantitation of HBVDNA in serum. In addition, results of
HBsAg by Architect and HBVDNA by screening kits were also
compared.
Results: 325 positive results and 69 negative results were
found in 394 samples by reagent II. 216 311 positive results
were found in the 325 positve samples and 38 69 negative
results were detected in the 69 negative samples by 5
screening kits; The lowest concentration of HBVDNA by the
foreign NAT kit and A/B/C domastic kit were 6 IU/mL and 50
IU/mL, respectively. The domestic kit D had false-positive
results. In addition, 285 positive results and 109 negative
results of HBsAg were detected in 394 samples by Artichtect
HBsAg. 212 282 positive results for HBVDNA were found in
the 285 positve samples for HBsAg and 49 105 negative
results for HBVDNA were found in 109 negative samples
for HBsAg by 5 screening kits. Most of the different results
came from the sera with HBVDNA concentration lower than
100 IU/mL.
Conclusions: Domastic reagents of HBV/HCV/HIV-1 for
HBVDNA have lower sensitivity than foreign reagent. Further
studies shall be concentrat on the accuracy of both foreign
and domestic NAT reagents.
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Background and Objectives: In order to play the role of
general practitioners in prevention and treatment of chronic
hepatitis B better, we investigated the current level of the
awareness and treatment capabilities of chronic hepatitis B
among the general practitioners.
Methods: A written examination survey was conducted to
102 general practitioners in a district of Beijing. They came
from 40 regional community health service centers, 2 or 3
doctors per center.
Results: The survey revealed that 58.8% of general
practitioners knew the basic diagnostic points, and 91.2%
were aware of the control of disease prevention. Whereas,
only 56.8% of the surveyed doctors were aware of the
severity of the disease and could make a correct assessment
of prognosis of the disease. Only 27.5% had the antivirus
therapy concept. Only 19.6% knew the common side effects
of interferon, and 6.9% knew the types of antiviral drugs
and were sure of which agent to use.
Conclusion: To facilitate the hepatitis B patients to be
better managed in both of the specialty hospitals and
the community, improving the level of the awareness and
practice of chronic hepatitis B management in general
practitioner community seems warranted and professional
knowledge training is necessary.
The research was supported by the major science and
technology project foundation of the national eleventh ﬁve-
year plan (No. 2009ZX10004-903).
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Background: Many viruses have evolved strategies to
modulate the activity of NK cells in response to the selective
pressure exerted by NK cells, such as envelope protein E2
of HCV, UL16 of HCMV, et al. Whether Hepatitis B virus
can produce any protein that can modulate the activity
of NK cells is not clear. Here in the present research, we
